Swiss pharmaceutical giant Roche (ROG: SIX) this morning revealed that sales for the first half of 2023 had dropped 2% to 29.78 billion Swiss francs ($33.01 billion), or -8% in franc terms, hit by weakness in its diagnostics division that saw booming demand during the height of the covid pandemic.
Pharmaceutical Division sales were up 8% at 22,681 million francs, while the Diagnostics Division’s revenues plunged 23% to 7,098 francs.
Group core operating profit fell 6% to 10,911 million francs, with diluted core earnings per share (EPS) declining 5% to 10.10 francs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze